ArticleBMC cardiovascular disorders2025
Association between Neutrophil-to-Lymphocyte ratio and left ventricular hypertrophy in chronic kidney disease patients: a cross-sectional study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between routine blood count-derived inflammatory markers and left ventricular hypertrophy in diabetic kidney disease patients: a cross-sectional study.Frontiers in clinical diabetes and healthcare · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundLeft ventricular hypertrophy (LVH) is a common cardiovascular complication in chronic kidney disease (CKD), associated with increased morbidity and mortality. Systemic inflammation may contribute to LVH, but evidence remains limited in non-dialysis CKD populations. The neutrophil-to-lymphocyte ratio (NLR), a readily accessible inflammatory marker, may serve as a predictor of LVH.
methodsIn this cross-sectional study, 514 hospitalized CKD patients were enrolled. LVH was defined by echocardiographic criteria based on left ventricular mass index. NLR was calculated from complete blood counts. Logistic regression models were used to evaluate the association between NLR and LVH after adjusting for potential confounders. Subgroup and restricted cubic spline (RCS) analyses were conducted to assess consistency and non-linear relationships. Mediation analysis was performed to explore whether NLR mediated the relationship between CKD and LVH.
resultsPatients with LVH had significantly higher NLR levels than those without (3.14 vs. 2.20, p < 0.001). After full adjustment, standardized NLR remained independently associated with LVH (adjusted OR: 1.34, 95% CI: 1.05-1.72, p = 0.02). RCS showed a linear relationship between NLR and LVH risk (p for nonlinear = 0.229). Subgroup analyses confirmed this robust association across subgroups (p for interaction ≥ 0.05). Mediation analysis indicated that NLR partially mediated the relationship between CKD and LVH, accounting for 5.1% of the total effect.
conclusionElevated NLR was independently associated with LVH and may reflect underlying inflammatory processes involved in cardiac remodeling among patients with CKD. Given its simplicity and accessibility, NLR may serve as a potential marker for identifying individuals at increased cardiovascular risk, although further validation in prospective studies is warranted. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.